| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the First Department of Pathology,*
Niigata
University School of Medicine, Niigata, Japan; and the Department of
Pathology (II),
Juntendo University School of
Medicine, Tokyo, Japan
Genetic alterations of pancreatic intraductal lesions adjacent to invasive ductal carcinoma were investigated. We submitted nine foci of ordinary epithelium, 12 foci of nonpapillary hyperplasia, 12 foci of papillary hyperplasia (pap HP), 66 foci of severe ductal dysplasia, and 27 invasive foci from a total of 10 pancreatic carcinomas for genetic analysis. All foci were individually microdissected and allelic losses of 3p, 4q, 5q, 6q, 8p, 9p, 10q, 11q, 13q, 16q, 17p, and 18q were studied. All invasive and severely dysplastic intraductal foci exhibited loss of heterozygosity (LOH) at more than one chromosomal locus. For each case, allelic loss was frequently observed on 9p (severe ductal dysplasia 90%, invasion 100%), 17p (severe ductal dysplasia 80%, invasion 80%), and 18q (severe ductal dysplasia 88%, invasion 88%). Ninety-four percent of severe ductal dysplasia and 96% of invasive foci had multiple LOH. Seventeen percent of nonpapillary hyperplasia and 33% of pap HP showed LOH. Only one focus of pap HP showed multiple LOH. The patterns of allelic loss identified in severe ductal dysplasia were generally conserved in synchronous infiltrating tumors, supporting the paradigm that infiltrating tumors are clonally derived from severe ductal dysplasia. In eight of 10 cases, however, we found frequent genetic heterogeneity in the intraductal lesion, suggestive of genetic progression or diversion. These findings indicate that invasive pancreatic carcinoma evolves through successive and divergent genetic changes with selection of aggressive subclones in the intraductal component.
This article has been cited by other articles:
 |
|
 |
|
  G. Feldmann and A. Maitra Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Ji, F. C. Mei, J. Xie, and X. Cheng Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells J. Biol. Chem., May 11, 2007; 282(19): 14048 - 14055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Takahashi, T. Oda, T. Hasebe, Y. Aoyagi, T. Kinoshita, M. Konishi, T. Nakagohri, K. Inoue, S. Takahashi, H. Kawahira, et al. Biologically Different Subgroups of Invasive Ductal Carcinoma of the Pancreas: Dpc4 Status According to the Ratio of Intraductal Carcinoma Components Clin. Cancer Res., June 1, 2004; 10(11): 3772 - 3779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Marchetti, F. Barassi, C. Martella, A. Chella, S. Salvatore, A. Castrataro, F. Mucilli, R. Sacco, and F. Buttitta Down Regulation of High in Normal-1 (HIN-1) is a Frequent Event in Stage I Non-Small Cell Lung Cancer and Correlates with Poor Clinical Outcome Clin. Cancer Res., February 15, 2004; 10(4): 1338 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Aguirre, N. Bardeesy, M. Sinha, L. Lopez, D. A. Tuveson, J. Horner, M. S. Redston, and R. A. DePinho Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma Genes & Dev., December 15, 2003; 17(24): 3112 - 3126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Roca, R. M. Kypta, and M. d. M. Vivanco Loss of p16INK4a results in increased glucocorticoid receptor activity during fibrosarcoma development PNAS, March 18, 2003; 100(6): 3113 - 3118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Howes and J P Neoptolemos Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis Gut, December 1, 2002; 51(6): 765 - 766. [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Biankin, J. G. Kench, A. L. Morey, C.-S. Lee, S. A. Biankin, D. R. Head, T. B. Hugh, S. M. Henshall, and R. L. Sutherland Overexpression of p21WAF1/CIP1 is an Early Event in the Development of Pancreatic Intraepithelial Neoplasia Cancer Res., December 1, 2001; 61(24): 8830 - 8837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Krop, D. Sgroi, D. A. Porter, K. L. Lunetta, R. LeVangie, P. Seth, C. M. Kaelin, E. Rhei, M. Bosenberg, S. Schnitt, et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells PNAS, July 24, 2001; (2001) 171138398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Wilentz, P. Argani, and R. H. Hruban Loss of Heterozygosity or Intragenic Mutation, Which Comes First? Am. J. Pathol., May 1, 2001; 158(5): 1561 - 1563. [Full Text] [PDF]
|
|
|
|
|
|
J. Luttges, H. Galehdari, V. Brocker, I. Schwarte-Waldhoff, D. Henne-Bruns, G. Kloppel, W. Schmiegel, and S. A. Hahn Allelic Loss Is Often the First Hit in the Biallelic Inactivation of the p53 and DPC4 Genes During Pancreatic Carcinogenesis Am. J. Pathol., May 1, 2001; 158(5): 1677 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Hruban, M. Goggins, J. Parsons, and S. E. Kern Progression Model for Pancreatic Cancer Clin. Cancer Res., August 1, 2000; 6(8): 2969 - 2972. [Full Text]
|
|
|
|
|
|
R. H. Hruban, R. E. Wilentz, and S. E. Kern Genetic Progression in the Pancreatic Ducts Am. J. Pathol., June 1, 2000; 156(6): 1821 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Krop, D. Sgroi, D. A. Porter, K. L. Lunetta, R. LeVangie, P. Seth, C. M. Kaelin, E. Rhei, M. Bosenberg, S. Schnitt, et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells PNAS, August 14, 2001; 98(17): 9796 - 9801. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
